HECEIVED

APR 2 9 2003 7

TECH CENTER 1600|2900



In the United States Patent & Trademark Office

In re Application of:

Hott, J.S. et al.

Serial No.:

10/005,512

Filed on:

November 7, 2001

For:

An Immunotoxin (mAB-

RICIN) for the Treatment of

Focal Movement Disorders

Examiner:

Nolan, P.J.

Art Unit:

1644

Atty. Dkt.:

03514.159

Reply

Hon. Director of Patents and Trademarks Washington, D.C. 20231

Sir:

In Response to the Official Action of February 26, 2003, issued with respect to the above-identified patent application, the time for responding to which has been extended by the accompanying Request for an Extension of Time, Applicants respectfully request entry and consideration of the following Reply comprising Introductory Comments, Amendments to the Specification, Amendments to the Claims, and Remarks.

Introductory Comments

This Reply has been formatted in attempted compliance with the proposed revisions to 37 CFR 1.121.

No fee, other than those provided for on the accompanying Fee Transmittal Form are believed to be due in order for the timely consideration of this Reply. If, however, the Director determines that such a fee is required, then the Director is authorized to charge any (Large Entity) fee required for consideration of this submission to Deposit Account 50-0548.